Clinical Trial Update: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE [Phase 3]

View source ↗

Summary

Phase 3 study of Milvexian in participants after acute ischemic stroke or high-risk transient ischemic attack is actively not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Drugs mentioned

• Milvexian (milvexian)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Ischemic Stroke; Ischemic Attack, Transient | Phase 3 | Status: ACTIVE_NOT_RECRUITING